Mohamed Kharfan-Dabaja,MD, MBA
@mkd-bmt.bsky.social
Vice Chair of Hematology. Director of Blood Marrow and Transplantation and Cellular Therapies.@MayoClinic @MayoCancerCare
Views are my own.
Views are my own.
Reposted by Mohamed Kharfan-Dabaja,MD, MBA
Happy to share our recent manuscript on outcomes of anti-CD19 #CART for #lymphoma in octogenarians (80 years of age or older).
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Bone Marrow Transplantation - Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
rdcu.be
March 2, 2025 at 2:28 AM
Happy to share our recent manuscript on outcomes of anti-CD19 #CART for #lymphoma in octogenarians (80 years of age or older).
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
Reposted by Mohamed Kharfan-Dabaja,MD, MBA
How I Treat #BPDCN
@ash-hematology.bsky.social @mkd-bmt.bsky.social #ASH24 #leusm
ashpublications.org/blood/articl...
@ash-hematology.bsky.social @mkd-bmt.bsky.social #ASH24 #leusm
ashpublications.org/blood/articl...
December 5, 2024 at 4:16 AM
Reposted by Mohamed Kharfan-Dabaja,MD, MBA
If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW
November 22, 2024 at 2:33 PM
If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW